Product Name: ErbB2-2
Product Number: AB-NK054-5
Size: 25 µg      Price:89.00
      $US
Target Full Name: ErbB2 (Neu) receptor-tyrosine kinase

Target Alias: CD340; C-erbB-2; Epidermal growth factor receptor-related protein; ErbB2; HER2; HER-2; Kinase ErbB2; MLN 19; V-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); TKR1; hCG_28177; ENSG00000141736; Q9NP09; Q9UK79

Product Type Specific: Protein kinase pan-specific antibody

Antibody Code: NK054-5

Antibody Target Type: Pan-specific

Protein UniProt: P04626

Protein SigNET: P04626

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Human ErbB2 (HER2, Neu) sequence peptide Cat. No.: PE-01ATW85

Antibody Immunogen Sequence: QLALTLIDTNRSRAC

Antibody Immunogen Description: Corresponds to amino acid residues Q178 to C192; In the extracellular domain of the receptor.

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 0.33 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Potency: Medium immunoreactivity with recombinant human ErbB2 on protein dot blots.

Antibody Species Reactivity: Human

Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 138, 175-200 kDa.

Antibody Specificity: High
Antibody Cross Reactivity: Medium immunoreactivity on protein dot blots with recombinant human EGFR, and no immunoreactivity with ErbB4.

Related Product 1: ErbB2-2 blocking peptide

Related Product 2: ErbB2 pan-specific antibody (Cat. No.: AB-NK054-3)

Related Product 3: ErbB2 pan-specific antibody (Cat. No.: AB-NK054-4P)

Related Product 4: ErbB2-1 pan-specific antibody (Cat. No.: AB-NK054-4)

Related Product 5: ErbB2-3 pan-specific antibody (Cat. No.: AB-NK054-6)

Related Product 6: ErbB2-4 pan-specific antibody (Cat. No.: AB-NK054-7)

Related Product 7: ErbB2-pY1248 phosphosite-specific antibody (Cat. No.: AB-PK613)

Scientific Background: ErbB2 (HER2, Neu) is a protein-tyrosine kinase of the TK group and EGFR family. It is a kinase that function as a component of several membrane protein receptor complexes on the cell surface. Specifically, the ErbB2 protein functions in the regulation of the growth and stabilization of peripheral microtubules, as well as in the transcriptional activation of several rRNA genes (mediated by RNA polymerase I) that result in enhanced protein synthesis and subsequent cell growth. It is highly expressed and widely distributed in most tested human tissues except in the brain and spinal cord, where it is more moderately expressed. Protein interaction is induced with phosphorylation of Y1139 (with Grb2, Grb7 & Src), Y1196 (with Crk), and Y1222 (with CGI-27, Grb2 & Shc1). Phosphorylation of Y1112 induces interaction with Cbl, which promotes ErbB2 degradation. Overexpression of unaltered ErbB2 coding sequences in NIH-3T3 cells results in cellular transformation and tumorigenesis. ErbB2 is amplified in about 30% of primary human breast malignancies and overexpression of ErbB2 is associated with the most aggressive tumours that show uncontrolled proliferation, resistance to apoptosis and increased motility. ErbB2 has also been linked with the development of ovarian cancer, gastric and lung adenocarcinomas, and glioblastomas. Insertional mutagenesis studies in mice also support a role for this protein kinase in mouse cancer oncogenesis.
Figure 1. Dot blotting ErbB2-2 antibody with recombinant purified proteins.